ReviewDrug design, development and therapy2023
Oral Isotretinoin and Its Uses in Dermatology: A Review.
Review in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of isotretinoin on bone dynamics in the craniomaxillofacial region: a systematic review of preclinical evidence.European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry · 2026Pooled it
- Individualizing isotretinoin dosing in acne: comparable 24-week efficacy and better tolerability at lower daily doses.Frontiers in medicine · 2026Pooled it
- Continuous alternate day vs intermittent daily fixed doses of oral isotretinoin in grade 2 acne vulgaris.The Indian journal of medical research · 2026Trial
- Management of Treatment Resistant EGFR Inhibitor-Induced Papulopustular Exanthema With Isotretinoin and Dapsone.The Australasian journal of dermatology · 2026Article
- The Latest Advances in Rosacea Treatment: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Expert Consensus on the Rational Approach to Isotretinoin Usage for Effective Management of Acne: ERAISE ACNE Recommendations.Dermatology and therapy · 2026Review
- The Role of Chemopreventive Agents in the Management of Oral Potentially Malignant Disorders and Oral Cancer: A Narrative Review.Cancer reports (Hoboken, N.J.) · 2026Review
- Isotretinoin Beyond the Skin: A Prospective Study on Its Impact on Periodontal Health.Dermatology practical & conceptual · 2026Article
- Case Report: A case of Rothmund-Thomson syndrome-like phenotype with anFrontiers in medicine · 2026Article
- Chronic administration of isotretinoin induces depressive- and anxiety-like behaviors by altering the neuroactive ligand-receptor interaction pathway in adolescent mice.Translational psychiatry · 2025Article
- Dorsal Nasal Skin Necrosis Following Rhinoplasty in Patients Treated with Topical Retinoids.Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India · 2025Article
- Real-World Evidence of Neuropsychiatric Adverse Reactions to Isotretinoin: Insights from EudraVigilance (2005-2025).Pharmaceuticals (Basel, Switzerland) · 2025Article
- Review
- Review
- Therapeutic Modulation of Demodex Density via Isotretinoin: Insights From a Prospective Dermatological Investigation.Journal of cosmetic dermatology · 2025Article
- Therapeutic Uses of Retinol and Retinoid-Related Antioxidants.Molecules (Basel, Switzerland) · 2025Review
- Off-Label Treatment in Inflammatory Skin Diseases-European Point of View.Journal of clinical medicine · 2025Review
- Isotretinoin Concerns in Switzerland: A Student-Based Transversal Study.Journal of clinical medicine · 2025Article
- Assessing the Psychosocial Impact of Acne Scars on Individuals With Pigmented Skin: A Multicenter Observational Study.Dermatology research and practice · 2025Article
- Retinoids in scarless skin regeneration: from molecular mechanisms to therapeutic strategies.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 1982, the Food and Drug Administration (FDA) of the United States of America approved isotretinoin (13-cis-retinoic acid), a retinoid derivative of vitamin A, to treat severe recalcitrant acne vulgaris. Apart from its prescribed use for severe acne, evidence suggests that isotretinoin is commonly used off-label to treat mild-to-moderate acne, inflammatory skin conditions, genodermatoses, skin cancer, and other skin disorders. This is due to its anti-inflammatory, immunomodulatory, and antineoplastic properties. Some "off-label" use is successful, while others are ineffective. Therefore, this information is essential to clinicians for deciding on the appropriate use of isotretinoin. In this article, we aim to review the most updated evidence-based data about the use of oral isotretinoin in dermatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.